Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease

Next Previous
Search
Trial Profile

An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emlenoflast (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Inflazome; Roche

Most Recent Events

  • 02 Dec 2020 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
  • 02 Dec 2020 Status changed from not yet recruiting to discontinued.
  • 17 Sep 2020 Planned End Date changed from 1 Sep 2020 to 1 Nov 2020.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top